A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2691-2693

  Covington, Paul S ^a   Davenport, J Michael ^a   Andrae, David A ^a   Stryjewski, Martin E ^b   Turner, Lisa L ^a   McIntyre, Gail ^a   Almenoff, June ^a  

^a Furiex Pharmaceuticals Inc   (United States)

^b CEMIC   (Argentina)

Author keywords

Cabp; pneumoniae; Respiratory pathogens; Streptococcus

Indexed keywords

AVAROFLOXACIN; CEFTAROLINE; JNJ Q 2; MOXIFLOXACIN; UNCLASSIFIED DRUG;

BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BACTERIUM DETECTION; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DRUG TREATMENT FAILURE; DYSPNEA; FEVER; GRAM STAINING; HUMAN; HYPOTHERMIA; LETTER; LUNG INFILTRATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZATION; SPUTUM; STREPTOCOCCUS PNEUMONIAE; TACHYPNEA; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

CABP; RESPIRATORY PATHOGENS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886310800     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt217     Document Type: Letter

References (10)

1. FDA. Guidance for Industry: Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment: March 2009. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM123686.pdf (7 November 2012, date last accessed).
2. Pertel P, BernardoP, FogartyCet al. Effects of prior effectivetherapyonthe efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46: 1142-51.
3. van der Eerden MM, Vlaspolder F, de Graaff CS et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomized study. Thorax 2005; 60: 672-8.
4. Garcia-Vazquez E, Marcos MA, Mensa J et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164: 1807-11.
5. Vernet G, Saha S, Satzke C et al. Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs. Clin Microbiol Infect 2011; 17: 1-13.
6. KlugmanKP, MadhiSA, AlbrichWC.Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis 2008; 47: 202-6.
7. File TM Jr, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405.
8. Aetna Inc. Clinical Policy Bulletin: Polymerase Chain Reaction Testing: Selected Indications. http://www.aetna.com/cpb/medical/data/600_699/ 0650.html (6 December 2012, date last accessed).
9. Yang S, Lin S, Khalil A et al. Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol 2005; 43: 3221-6.
10. Johansson N, Kalin M, Tiveljung-Lindell A et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50: 202-9.